

ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Aug 01, 2021




RESPIRATORY PATHOGEN PANEL 2021

Positivity Rate (%)


MONTH	FLU A	FLU H1 (H1-A)	2009 H1N1 (H1-B)	H3	FLU B	RSV A	RSV B	RSV A/B	PARA 1	PARA 2	PARA 3	Para 4 A	COR 229E	COR NL63	COR OC43	COR HKU1	META	E/R	ADENO	BOCA	LEG	CHL	MYCO
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1
JUL	0.0	0.0	0.0	0.0	0.0	0.9	6.4	7.3	0.1	0.5	11.5	0.0	0.1	0.3	1.2	0.0	0.4	16.8	1.5	3.9	0.3	0.0	0.0
AUG																							
SEP																							
OCT																							
NOV																							
DEC																							

Increased prevalence of viruses: **RSV (type B), Parainfluenza 3 and Rhinovirus.**

PARA3 POSITIVITY RATE 2021 (%)




RSV POSITIVITY RATE 2021 (%)





ACL RSVAG- Pos rate (%) - Aug 1, 2021

IL % RSVAG

WI % RSVAG





CDC Data RSV pos rate for Region 5 Chicago - (PCR - 16%, Antigen - 14%)




SARS-COV-2				Hologic Aptima		Influenza - no activity				RSVAG		
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % COV19	WI % COV19	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG
Aug 1	3.8	6.9	10.5	17.6	4.9	8.9	0	0	0	0	32.1	22.4
Jul 25	2.7	4.1	8.0	11.8	2.2	5.1	0	0	0	0	15.5	16.7
Jul 18	1.8	2.6	1.4	7.2	2.1	2.3	0	0	0	0	15.6	21.6
Jul 11	1.6	1.6	1.0	5.0	1.0	1.0	0	0	0	0	16.7	17.4
Jul 4	1.6	1.4	0.0	3.0	1.0	1.4	0	0	0	0	15.5	15.5
Jun 27	1.7	1.5	1.5	2.8	0.3	0.9	0	0	0	0	11.1	8.3
Jun 20	1.5	1.2	1.5	1.1	0.8	0.6	0	0	0	0	7.1	3.2
Jun 13	1.6	1.2	1.4	2.7	1.2	0.7	0	0	0	0	8.6	3.7
Jun 06	2.5	1.6	2.6	2.7	1.2	0.9	0	0	0	0	5.0	0.0
May 29	3.8	2.3	3.1	5.3	1.7	2.1	0	0	0	0	10.7	0.0
May 22	4.5	2.7	3.3	5.7	2.3	3.3	0	0	0	0	0.0	8.7
May 15	5.0	3.4	3.7	6.9	2.7	3.6	0	0	0	0	0.0	0.0
May 8	5.9	3.8	6.1	12.8	3.1	3.4	0	0	0	0	2.3	0.0

ACL RSVAG Antigen test results are consistent with “atypical” summer RSV outbreak


ACL COVAG and SCVPCR - Pos rate (%) - Jul 25, 2021



Jul 28, 2021 - daily COVID-19 cases in US - CDC




Jul 17, 2021 – SARS-CoV-2 circulating in the US (~82 % Delta variant)



US vaccination status CDC | Data as of: Jul 29, 2021



344,071,595 Vaccines Administered	
189,945,907 People who received at least one dose	163,868,916 People who are fully vaccinated*
57.2% Percentage of the US population that has received at least one dose	49.4% Percentage of the US population that has been fully vaccinated*

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 27, 2020 – July 24, 2021



2020-21 Influenza Season Week 29 ending Jul 24, 2021

ILI Activity Level



New York City


District of Columbia

Hawaii


Alaska

Puerto Rico

CSF targets positivity rate is 6.7% (VZV and HHV6)



The most prevalent GI bacterial target is (Campylobacter)



The most prevalent GI viral target is – Norovirus II – 0.4%

